Jaguar Animal Health (NASDAQ:JAGX) Announces Earnings Results

Jaguar Animal Health (NASDAQ:JAGX) issued its earnings results on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share for the quarter, topping the consensus estimate of ($782.25) by $766.55, Zacks reports. The company had revenue of $1.23 million for the quarter, compared to analyst estimates of $4.24 million.

Here are the key takeaways from Jaguar Animal Health’s conference call:

• Rare-disease focus and clinical catalysts: Jaguar is concentrating its human-health development efforts entirely on crofelemer for intestinal failure, with the MVID clinical package expected by the end of 2026, a potential NDA filing in mid-2027, and possible U.S. approval by late 2027 if breakthrough therapy designation is granted.
• Encouraging proof-of-concept data: Long-term treatment was associated with parenteral-support reductions of up to 48% in an MVID patient and up to 40% in SBS-IF patients, with relapse after treatment withdrawal and no reported crofelemer-related safety issues.
• Non-dilutive funding and partnering strategy: The Future Pak agreement provided $18 million in upfront payments, with up to $17 million in additional potential milestones, while Jaguar continues manufacturing the licensed products and is seeking a larger partner for its intestinal-failure program.
• Financial losses and revenue pressure remain significant: Second-quarter prescription-product revenue fell 60% year over year to approximately $1.2 million, net loss attributable to common shareholders widened to $12.7 million, and losses from debt extinguishment and fair-value adjustments increased.
• Animal-health expansion planned: Jaguar expects to launch Neonorm Dog through online and retail channels, including Amazon and Chewy, leveraging relationships developed through its former Canalevia-CA1 commercialization efforts.

Jaguar Animal Health Trading Down 1.5%

Jaguar Animal Health stock traded down $0.04 during midday trading on Monday, hitting $2.67. 69,675 shares of the stock were exchanged, compared to its average volume of 14,579. Jaguar Animal Health has a fifty-two week low of $2.35 and a fifty-two week high of $1,280.95. The stock has a market capitalization of $907,800.00, a price-to-earnings ratio of -0.01 and a beta of -0.07. The stock’s 50-day simple moving average is $13.35 and its 200 day simple moving average is $86.90. The company has a current ratio of 0.69, a quick ratio of 0.40 and a debt-to-equity ratio of 0.35.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on developing and commercializing medicines and health products for animals. The company’s research is centered on naturally derived compounds, particularly plant-based products designed to address gastrointestinal disorders and other health conditions in companion and production animals.

Jaguar’s portfolio and development programs include products for dogs, cats, horses and livestock. Its best-known product is Canalevia-CA1, a crofelemer-based prescription product that received conditional approval from the U.S.